for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

36.25USD

Change

0.23(+0.64%)

Volume

5,295,625

Today's Range

35.75

 - 

36.33

52 Week Range

27.89

 - 

40.93

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
36.02
Open
35.77
Volume
5,295,625
3M AVG Volume
588.28
Today's High
36.33
Today's Low
35.75
52 Week High
40.93
52 Week Low
27.89
Shares Out (MIL)
5,556.88
Market Cap (MIL)
200,158.80
Forward P/E
12.29
Dividend (Yield %)
4.22

Next Event

Q3 2020 Pfizer Inc Earnings Release

Latest Developments

更多

Onkure And Pfizer Enter Agreement To Evaluate Combination Of Oki-179 And Binimetinib

EMD Sereno Says Bavencio Pivotal Phase III Javelin Bladder 100 Results Published In The New England Journal Of Medicine

Pfizer Sees $18 - $20 Bln Lost Revenue Due To Exclusivity Losses Beginning In 2026 - Investor Day

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.53 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

52.5K

2018

53.6K

2019

51.8K

2020(E)

49.4K
EPS (USD)

2017

2.650

2018

3.000

2019

2.950

2020(E)

2.930
Price To Earnings (TTM)
14.66
Price To Sales (TTM)
4.07
Price To Book (MRQ)
3.11
Price To Cash Flow (TTM)
10.38
Total Debt To Equity (MRQ)
98.88
LT Debt To Equity (MRQ)
78.54
Return on Investment (TTM)
10.32
Return on Equity (TTM)
8.31

Latest News

Latest News

UPDATE 2-U.S. FDA to tighten coronavirus vaccine authorization standards ahead of election -paper

The U.S. Food and Drug Administration is expected to soon announce new, more stringent standards for an emergency authorization of a COVID-19 vaccine, lowering the chances that one might be cleared for use before the Nov. 3 election, the Washington Post reported on Tuesday.

FACTBOX- The race for a coronavirus vaccine

(Updates Moderna, adds Beijing Wantai Biological Pharmacy, COVAXX, University Hospital Tuebingen, China's Institute of Biotechnology) Sept 21 (Reuters) - More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human...

Trump suggests Pfizer could win U.S. COVID-19 vaccine approval, JNJ to come later

U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks, saying a contender by Johnson & Johnson could come later.

FOCUS-Pfizer vaccine trial bets on early win against coronavirus, documents show

Pfizer Inc is betting that its coronavirus vaccine candidate will show clear evidence of effectiveness early in its clinical trial, according to the company and internal documents reviewed by Reuters that describe how the trial is being run.

UPDATE 2-BioNTech buys German site from Novartis to boost vaccine output

* BioNTech CEO: Request for approval likely late-Oct, early-Nov

UPDATE 2-Pfizer says coronavirus vaccine study shows mostly mild-to-moderate side effects

Pfizer Inc said on Tuesday participants were showing mostly mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.

Pfizer says late-stage coronavirus vaccine study shows moderate side effects

Pfizer Inc said on Tuesday patients were showing mild-to-moderate tolerability to either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.

GLOBAL MARKETS-COVID-19 vaccine hopes lift world stocks, dollar eases

* UK parliament to vote on plan to break Brexit divorce treaty

Pfizer says enrolled more than 29,000 people in its COVID-19 vaccine trial

Pfizer Inc said on Monday that it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.

UPDATE 2-Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteers

Pfizer Inc and BioNTech SE on Saturday proposed to the U.S Food and Drug Administration (FDA) to expand their Phase 3 pivotal COVID-19 vaccine trial to about 44,000 participants while increasing the diversity of the trial population.

Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteers

Pfizer Inc and BioNTech SE have proposed to the U.S Food and Drug Administration (FDA) to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to about 44,000 participants, the companies said on Saturday.

BioNTech, Pfizer begin German part of COVID-19 vaccine study

Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany.

UPDATE 2-Pfizer sees COVID-19 vaccine data in thick of U.S. election fight

* Merck, Pfizer pledge to skirt politics, follow data (Adds details about Merck vaccine plans, comments from Pfizer CEO)

Pfizer targets end of October for COVID-19 vaccine update

U.S. drugmaker Pfizer said it should know by the end of October whether a COVID-19 vaccine it is developing is successful, and will submit it for approval immediately if that is the case.

FACTBOX-Dozens of countries host clinical trials of coronavirus vaccine candidates

As the race to develop a safe and effective coronavirus vaccine reaches its final stages, pharmaceutical companies have started conducting large human trials in different countries. Some countries also have signed supply deals with the companies. Below is a summary of clinical...

CORRECTED-EXCLUSIVE-Nearly a fifth of enrollees in Pfizer, BioNTech COVID-19 vaccine study are Black or Latino -exec

Nearly a fifth of 11,000 people enrolled so far in a 30,000-volunteer U.S. trial testing a COVID-19 vaccine from Pfizer and German partner BioNTech are Black or Latino, groups among the hardest hit by the coronavirus virus pandemic, a top Pfizer executive said.

Pfizer, BioNTech shares gain as more data backs vaccine candidate

Shares of Pfizer Inc and U.S.-listed shares of partner BioNTech SE rose on Friday after they released additional data for their experimental coronavirus vaccine and reiterated they were on track to seek a regulatory review in October.

UPDATE 3-Pfizer to make Gilead's COVID-19 treatment remdesivir

Pfizer Inc said on Friday it signed a multiyear agreement to make COVID-19 treatment remdesivir for developer Gilead Sciences Inc, which is under pressure to increase tight supplies of the antiviral drug.

Pfizer signs deal to supply Gilead's remdesivir for COVID-19

Pfizer Inc said on Friday it signed a multi-year agreement with Gilead Sciences Inc to manufacture and supply the company's antiviral drug remdesivir for COVID-19 patients.

UPDATE 4-Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccines

Canada has signed separate deals with Pfizer Inc and Moderna Inc to supply millions of doses of their experimental coronavirus vaccines, a top official said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up